クッシング病患者の治療におけるLCI699の安全性と有効性

基本情報

NCT ID

NCT02180217

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

137

治験依頼者名

Novartis

概要

The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with Cushing's disease in the US and the EU. This is a phase lll, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period which evaluated the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease.

対象疾患

介入

依頼者（Sponsor）